Bevacizumab for NF2‐associated vestibular schwannomas of childhood and adolescence
- 2 March 2020
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 67 (5), e28228
- https://doi.org/10.1002/pbc.28228
Abstract
Seventeen children at six institutions with neurofibromatosis type 2 (NF2)-related vestibular schwannomas received bevacizumab. Eight of the 13 patients with initial hearing loss (61%) showed objective hearing improvement within six months of treatment. No patients showed hearing deterioration during therapy; however, only two patients showed objective radiological response. Seven of eight patients had tumor progression or worsening hearing loss upon cessation of treatment. Bevacizumab was well tolerated with no patients discontinuing therapy. Bevacizumab appears to postpone hearing loss in childhood NF2-associated vestibular schwannomas, but responses are not durable, suggesting that either longer maintenance therapy or new strategies are required.Funding Information
- Canadian Institutes of Health Research
- Terry Fox Foundation
This publication has 13 references indexed in Scilit:
- An update on the diagnosis and treatment of vestibular schwannomaExpert Review of Neurotherapeutics, 2017
- Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2–Associated Vestibular SchwannomasJournal of Clinical Oncology, 2016
- Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluationNeuro-Oncology Practice, 2016
- Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patientsCancer Chemotherapy and Pharmacology, 2014
- Natural History of Vestibular Schwannoma Growth and Hearing Decline in Newly Diagnosed Neurofibromatosis Type 2 PatientsOtology & Neurotology, 2014
- Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2Otology & Neurotology, 2012
- The role of radiology in the diagnosis and management of vestibular schwannomaClinical Radiology, 2011
- Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]Genetics in Medicine, 2009
- Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2The New England Journal of Medicine, 2009
- National Institutes of Health Consensus Development Conference Statement on Acoustic Neuroma, December 11-13, 1991Archives of Neurology, 1994